Back to top

Verastem’s KRAS G12D Pancreatic Cancer Trial Advances: What Investors Should Watch

Verastem Inc ($VSTM) announced an update on their ongoing clinical study. The Phase 2 study “A Phase 2 Study of VS-7375 in Patients With KRAS G12D-...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Verastem, Inc. (VSTM)